Brief: Neurosense Receives Regulatory Approval To Commence Patient Enrollment In Italy For Phase 2B Trial In ALS

Neurosense Therapeutics

16/11/2022 14:30

Nov 16 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE RECEIVES REGULATORY APPROVAL TO COMMENCE
PATIENT
ENROLLMENT IN ITALY FOR ITS PHASE 2B TRIAL IN ALS
    * NEUROSENSE THERAPEUTICS LTD - HAS RECEIVED APPROVAL FROM
THE
ITALIAN MEDICINES AGENCY (AIFA) TO COMMENCE PATIENT ENROLLMENT
IN ITALY FOR PARADIGM
    * NEUROSENSE THERAPEUTICS LTD - EXPECTS TO ENROLL AND DOSE
THE
FIRST PATIENTS IN ITALY AND IN THE U.S. IN THE NEXT FEW WEEKS

Further company coverage:  NRSN.O